title: Antitumor activity of imatinib mesylate in neuroblastoma xenografts.
abstract: Imatinib mesylate has antitumor activity in vitro and in vivo against neuroblastoma cell lines and xenografts characterized by a different expression of receptor tyrosine kinases. In this article, we report that imatinib tumor concentration can be independent of the administered dose and does not correlate with the antitumor effect. In xenografts, high-dose administration does not improve imatinib efficacy. In conclusion, there is no clear-cut correlation between the levels of expression for imatinib-responsive targets and the in vitro and in vivo sensitivity. This further suggests that in neuroblastoma the antitumor activity of imatinib may involve the inhibition of other tyrosine kinases and/or pathways.
authors.affiliation: Department of Pediatrics, Catholic University, Rome, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Meco
authors.forename: Anna
authors.initials: A
authors.lastname: Riccardi
authors.forename: Tiziana
authors.initials: T
authors.lastname: Servidei
authors.forename: Josef
authors.initials: J
authors.lastname: Brueggen
authors.forename: Marco
authors.initials: M
authors.lastname: Gessi
authors.forename: Riccardo
authors.initials: R
authors.lastname: Riccardi
authors.forename: Carlo
authors.initials: C
authors.lastname: Dominici
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001483:Base Sequence; D001549:Benzamides; D045744:Cell Line, Tumor; D017931:DNA Primers; D006801:Humans; D000068877:Imatinib Mesylate; D051379:Mice; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C464561:CGP 74588; D017931:DNA Primers; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate